AML cells with FLT3-ITD or NPM1 mutations are correlated with significantly increased levels of CD123 as compared to AML cells with wild-type FLT3 or NPM1 (Ehninger et al., 2014; Cortes et al., 2018; Cruz et al., 2018). The gene discussed is FLT3; the disease is acute myeloid leukemia.